# Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

> **NCT04082325** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 68 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lu AF88434
- **DRUG:** Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
- **DRUG:** Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04082325
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2020-09-24
- **Final completion:** 2020-09-24
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082325, "Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04082325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*